The
Data and Safety Monitoring Board determined that Cyclacel
Pharmaceuticals Inc.’s (Nasdaq: CYCC) ongoing Phase 3 study of
sapacitabine
was not likely to demonstrate statistically significant improvement in
survival. The stock price plummeted $2.15 to close at $0.68.
Cyclacel Pharmaceuticals reports disappointing data
December 16, 2014 at 11:30 AM EST
